Khosrow-Khavar F, et al. - Given the link between aromatase inhibitors and cardiovascular outcomes in women with breast cancer is controversial, researchers utilized the UK Clinical Practice Research Datalink connected to the Hospital Episode Statistics and Office for National Statistics databases in this population-based cohort analysis to compare myocardial infarction, ischemic stroke, heart failure, and cardiovascular mortality among new users of aromatase inhibitors vs new users of tamoxifen in a sample of women who were newly diagnosed with breast cancer and started hormonal therapy with aromatase inhibitors or tamoxifen. Overall 23,525 patients were included. Findings revealed increased risks of heart failure and cardiovascular mortality in relation to aromatase inhibitors vs tamoxifen. Trends toward raised risks, although nonsignificant, of myocardial infarction and ischemic stroke were also observed. Experts recommended balancing the increased risk of cardiovascular events related to aromatase inhibitors with their favorable clinical advantages vs tamoxifen.